Compile Data Set for Download or QSAR
maximum 50k data
Found 79 of ic50 for UniProtKB: P0DP23
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588519(US11542290, Compound MT-035)
Affinity DataIC50:  240nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588481(US11542290, Compound A-7)
Affinity DataIC50:  470nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand InfoPurchase
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588520(US11542290, Compound MT-036 | US11542290, Compound...)
Affinity DataIC50:  850nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588491(US11542290, Compound MT-009)
Affinity DataIC50:  860nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588490(US11542290, Compound MT-008)
Affinity DataIC50:  900nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588513(US11542290, Compound MT-030a)
Affinity DataIC50:  1.01E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM79181(10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoro...)
Affinity DataIC50:  1.06E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM79181(10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoro...)
Affinity DataIC50:  1.06E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM79181(10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoro...)
Affinity DataIC50:  1.11E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588484(US11542290, Compound MT-002)
Affinity DataIC50:  1.41E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588512(US11542290, Compound MT-030)
Affinity DataIC50:  1.65E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588485(US11542290, Compound MT-003)
Affinity DataIC50:  1.73E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588508(US11542290, Compound MT-026)
Affinity DataIC50:  2.03E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588501(US11542290, Compound MT-019)
Affinity DataIC50:  2.83E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588489(US11542290, Compound MT-007)
Affinity DataIC50:  2.97E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588515(US11542290, Compound MT-031a)
Affinity DataIC50:  2.97E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588520(US11542290, Compound MT-036 | US11542290, Compound...)
Affinity DataIC50:  2.99E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588487(US11542290, Compound MT-005)
Affinity DataIC50:  3.17E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588522(US11542290, Compound MT-038)
Affinity DataIC50:  3.90E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588505(US11542290, Compound MT-023)
Affinity DataIC50:  3.96E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588518(US11542290, Compound MT-034)
Affinity DataIC50:  4.10E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588493(US11542290, Compound MT-011)
Affinity DataIC50:  4.47E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588510(US11542290, Compound MT-028)
Affinity DataIC50:  4.83E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588517(US11542290, Compound MT-033)
Affinity DataIC50:  4.99E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50081950(6-Hydroxy-2-phenyl-chromen-4-one | 6-Hydroxyflavon...)
Affinity DataIC50:  5.17E+3nMAssay Description:Inhibition of human recombinant calmodulin assessed as inhibition of calmodulin-sensitive cAMP phosphodiesterase activation after 15 mins by spectrop...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50266274(14-methoxytajixanthone | CHEMBL515370)
Affinity DataIC50:  5.54E+3nMAssay Description:Inhibition of recombinant calmodulin (unknown origin) mediated bovine brain PDE1 activation assessed as effect on inorganic phosphate release by spec...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50266275(CHEMBL456494 | Tajixanthone hydrate)
Affinity DataIC50:  5.62E+3nMAssay Description:Inhibition of recombinant calmodulin (unknown origin) mediated bovine brain PDE1 activation assessed as effect on inorganic phosphate release by spec...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588494(US11542290, Compound MT-012)
Affinity DataIC50:  5.65E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588507(US11542290, Compound MT-025)
Affinity DataIC50:  6.70E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588506(US11542290, Compound MT-024)
Affinity DataIC50:  7.02E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50001888((chloropromazine) [3-(2-Chloro-phenothiazin-10-yl)...)
Affinity DataIC50:  7.26E+3nMAssay Description:Inhibition of recombinant calmodulin (unknown origin) mediated bovine brain PDE1 activation assessed as effect on inorganic phosphate release by spec...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588516(US11542290, Compound MT-032)
Affinity DataIC50:  7.43E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588498(US11542290, Compound MT-016)
Affinity DataIC50:  7.82E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588503(US11542290, Compound MT-021)
Affinity DataIC50:  8.13E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588514(US11542290, Compound MT-031)
Affinity DataIC50:  8.93E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588509(US11542290, Compound MT-027)
Affinity DataIC50:  9.03E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50346822(CHEMBL66917)
Affinity DataIC50:  9.38E+3nMAssay Description:Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 minMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50266273(15-chlorotajixanthone hydrate | CHEMBL458017)
Affinity DataIC50:  9.59E+3nMAssay Description:Inhibition of recombinant calmodulin (unknown origin) mediated bovine brain PDE1 activation assessed as effect on inorganic phosphate release by spec...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588496(US11542290, Compound MT-014)
Affinity DataIC50:  9.60E+3nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50001888((chloropromazine) [3-(2-Chloro-phenothiazin-10-yl)...)
Affinity DataIC50:  1.03E+4nMAssay Description:Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 minMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM7460(2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chrome...)
Affinity DataIC50:  1.30E+4nMAssay Description:Inhibition of human recombinant calmodulin assessed as inhibition of calmodulin-sensitive cAMP phosphodiesterase activation after 15 mins by spectrop...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588502(US11542290, Compound MT-020)
Affinity DataIC50:  1.39E+4nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588511(US11542290, Compound MT-029)
Affinity DataIC50:  1.39E+4nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50346811(CHEMBL1796022)
Affinity DataIC50:  1.50E+4nMAssay Description:Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 minMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM588504(US11542290, Compound MT-022)
Affinity DataIC50:  1.53E+4nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50346820(CHEMBL1796013)
Affinity DataIC50:  1.84E+4nMAssay Description:Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 minMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM23419((2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro...)
Affinity DataIC50:  2.20E+4nMAssay Description:Inhibition of human recombinant calmodulin assessed as inhibition of calmodulin-sensitive cAMP phosphodiesterase activation after 15 mins by spectrop...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50346810(CHEMBL268559)
Affinity DataIC50:  2.25E+4nMAssay Description:Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 minMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50346806(CHEMBL1796026)
Affinity DataIC50:  2.29E+4nMAssay Description:Inhibition of Calmodulin-dependent PDE1 activity assessed as inorganic phosphate release after 30 minMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCalmodulin-1(Human)
Camp4 Therapeutics

US Patent
LigandPNGBDBM50375645(CHEMBL219301 | US11542290, Compound A-3)
Affinity DataIC50:  2.41E+4nMAssay Description:The competition binding assay was performed in a 384-well plate format and in 20 μl reactions. Serial dilutions (0.001-100 μM) of a test co...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 79 total ) | Next | Last >>
Jump to: